NPPA Caps Trade Margins on 137 Anti-Cancer Drugs, Consumers Expected to Save Rs. 3,540 Crore Annually

The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has capped trade margins on the Maximum Retail Price (MRP) of 137 anti-cancer drugs, based on the recommendations of an Expert Committee constituted by the Directorate General of Health Services (DGHS), Ministry of Health & Family Welfare, on 17th October, 2026. The revised MRPs for these medicines take effect today, 9th November, 2026.

As of the 8th of November, 2026, 85 pharmaceutical companies have reported revised MRPs for 1,364 anti-cancer formulations, covering 121 drugs. 679 brands reported price reductions of more than 50%. The highest reported MRP reduction is 96.45%. As a result of the price reductions, the estimated annual savings to consumers are expected to be ₹3,540.38 crore.

Consumers can check the revised MRP printed on the medicine pack and verify medicine prices through the Pharma Sahi Daam mobile app or the NPPA website (nppa.gov.in). No chemist or hospital pharmacy can charge more than the revised MRP. In case of overcharging or any other pricing-related complaint, consumers can register their grievance through the Pharma Jan Samadhan portal or contact the NPPA helpline at 1800-111-255.

Source:https://news.docthub.com/nppa-caps-trade-margins-on-137-anti-cancer-drugs-consumers-expected-to-save-rs-3-540-crore-annually-N2704